News & Updates

The role of oral antivirals in COVID-19 treatment: Who, when, and how?

Though most countries have eased pandemic restrictions, there is no room for complacency in managing COVID-19, which continues to cause significant morbidity and mortality.

At a recent symposium, esteemed experts Dr Roger Paredes, Head of Department of Infectious Diseases at the Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, and Dr Nicola Petrosillo, Head of the Infection Prevention and Control and Infectious Disease Service at University Hospital Campus Bio-Medico, Rome, Italy, gave global perspectives on the continuing unmet needs in the COVID-19 outpatient landscape and discussed the role of antiviral treatment options in patients at risk of progressing to severe COVID-19. Dr Petrick Periyasamy, Head of Infectious Diseases Unit, Medical Department, UKM Medical Centre, Kuala Lumpur, Malaysia, chaired the session.

Monitoring Epstein–Barr viral load may reduce PTLD incidence after liver transplant

Epstein‒Barr virus (EBV) viral load (VL) monitoring can help lower the incidence of post-transplant lymphoproliferative disease (PTLD) following liver transplant in adults, suggests a study.

Digital misinformation may lead to wrong health decisions, says study

An online cross-sectional survey involving antivaxxers, conspiracy theorists, and flat earthers reveals how these people are more likely to believe in false causes of cancer, indicating an association between digital misinformation and consequent erroneous health decisions.

Regional antibiotic delivery a viable option for patients with device implant infections

Delivery of continuous, in situ–targeted, ultrahigh concentration of antibiotics (CITA) is a safe and effective therapy for patients with pocket infection who are neither suited nor willing to undergo extraction of implanted cardiovascular electronic device, reports a study.

Tix–cil combo prevents COVID-19 complications in immunocompromised patients

The combination of tixagevimab and cilgavimab (Tix-Cil) protects immunocompromised patients with suboptimal immune responses to vaccines from COVID-19 complications, results of a study have shown.